1. Introduction {#sec1}
===============

In March 1976, the first renal transplantation in Egypt was carried out at the Department of Urology, University of Mansoura. A mother donated one of her kidneys to her daughter who was suffering from end-stage renal disease secondary to chronic pyelonephritis. Armed only with azathioprine and corticosteroids, the operative procedure and the functional outcome were very successful. A typical example of beginner\'s luck. Following a very slow start, the number of procedures increased gradually until it has currently reached a rate exceeding 80 cases every year. Herein, our long-term results are reported with an analysis of factors which can have an impact on patients and graft survival.

2. Patients and Methods {#sec2}
=======================

2.1. Patients {#sec2.1}
-------------

Between March 1976 and March 2008, 1967 consecutive living donor renal transplants were carried out at the Urology & Nephrology Center, Mansoura University, Egypt. There were 1620 related and 347 unrelated donors. For recipients, our exclusion criteria included sensitization with positive lymphocytotoxic cross match and donor specific antibodies, recent malignancy, addiction, psychiatric disorders, type I diabetes mellitus, and significant extrarenal organs failure (pulmonary, hepatic, and cardiac). Absolute contraindications for donation included active infections, diabetes, even minimal renal function impairment, arterial hypertension, and serological positivity for HBV or HCV. Over the years, different immunosuppression regimens were utilized with or without an induction treatment. Azathioprine-based therapy was initially employed. Later on, a cyclosporine-based protocol was adopted \[[@B1]\]. Subsequently, triple immunosuppression regimens were utilized \[[@B2]\] Currently, steroid and/or calcineurin inhibitor-free protocols are the subject of several clinical trials \[[@B3], [@B4]\].

Approval of our Institutional Review Board (IRB) Committee was obtained.

2.2. Follow-Up {#sec2.2}
--------------

Patients were closely and regularly followed up for evaluation of renal function, the onset of surgical or medical complications, and side effects of immunosuppression. The median observation period was 7.47 years (range: 0--31.15 years).

2.3. Statistical Analysis {#sec2.3}
-------------------------

Actuarial survival was estimated by the Kaplan-Meier method. The log derivation of the percent survival was utilized for construction of graphs to predict the half-life of grafts and/or patients. Univariate analysis was carried out to correlate the graft survival to various preoperative, operative, and postoperative variables. Differences in survival were determined by the log-rank test. A *P* value of ≤0.05 was considered significant. For the determination of those factors who had an independent impact on graft survival, a Cox proportional hazard analysis was utilized. The variables included in this analysis were only those which were significant with the univariate study.

3. Results {#sec3}
==========

The overall actuarial graft survival was 86.7% and 65.5% at 5 and 10 years, respectively. The corresponding patient survival was 89.7% and 77.8% ([Figure 1](#fig1){ref-type="fig"}). The graft survival was essentially stable throughout the first 5 years. A negative and steady decline was observed thereafter. The projected half-life for grafts was 17.5 years and for recipients was 22 years ([Figure 2](#fig2){ref-type="fig"}).

Of the demographic variables, 3 had a significant negative impact on graft survival: donor\'s sex, donor\'s age, and recipient\'s age ([Table 1(a)](#tab1){ref-type="table"}). Our data suggest that recipients who did not receive a blood transfusion had a better outcome ([Table 1(b)](#tab1){ref-type="table"}). The number of class I and/or class II mismatches had a significant negative impact on graft survival. When both classes were pooled together, 2 observations could be made: the greater the number of mismatches the poorer was the result. Furthermore, there was a very clear separation in the prognostic outcome if the total number of mismatches was 2 or less versus 3 or more. It was also noted that HLA-identical siblings had the best short- and long-term graft and patient survival ([Table 1(c)](#tab1){ref-type="table"}). The nature of the original kidney disease, if it was identified, had a marginal negative impact on graft survival. Other current or past medical disorders did not have an influence ([Table 1(d)](#tab1){ref-type="table"}).

Of the technical variables, 2 had a significant effect on graft survival: the time to diuresis and the total ischemia time ([Table 2](#tab2){ref-type="table"}). Four post-transplant factors had a significant impact on graft survival: the primary immunosuppression ([Figure 3](#fig3){ref-type="fig"}), the number of acute rejection episodes, the total dose of steroid during the first 3 months, and post-transplant hypertension ([Table 3](#tab3){ref-type="table"}).

Of all the factors which had a significant impact on graft survival by univariate analysis, only 5 sustained their significance when the step-wise regression analysis was carried out ([Table 4](#tab4){ref-type="table"}). In this analysis, evidence was provided that donor\'s age, genetic considerations, primary immunosuppression, number of acute rejection episodes, and total steroid dose during the first 3 months acted as independent variables which had a significant influence on graft survival.

4. Discussion {#sec4}
=============

Over recent years, there has been a global increase in the number of live-donor kidney transplants in view of a severe shortage in the availability of deceased donor organs \[[@B5], [@B6]\]. The results of live-donor transplantation are generally superior to those obtained from deceased donors \[[@B7]\]. This can be explained, at least partially, by the short ischemia time. Factors inherent to the transplanted organ itself can also play an important role. Live donors are subject to rigorous predonation assessment. Furthermore, they are not exposed to major cardiovascular instability, sepsis, or nephrotoxic agents that may occur during hospitalization before declaration of brain death \[[@B8]\]. Our study relies only on an analysis of results of living donation. The overall graft survival was 86.7% and 65.5% at 5 and 10 years, respectively, with a projected half-life of 17.5 years. This compares favorably with recently published data \[[@B7], [@B9]\]. Out of the 1967 donors, 347 were unrelated (16.7%). The probability of graft survival among related and unrelated donors was essentially similar. This is consistent with previously published reports \[[@B10]\]. It is of interest to note that the use of unrelated donors led to a higher graft survival than related ones in certain conditions, namely, type I DM, focal glomerulosclerosis and polycystic kidney disease \[[@B11]\].

In our report, factors that can possibly have an influence on graft and patient survival were evaluated by univariate as well as by multivariate analysis. Out of all the studied variables, only 5 had an independent impact on the graft survival: the donor\'s age, the genetic considerations, the type of primary immunosuppression, the number of acute rejection episodes, and the total dose of steroids during the first 3 months after transplantation. It is noteworthy that the postoperative urologic complications in this series did not have a significant impact on patient and graft survival. The nature of such complications and their impact on patient and graft survival had been fully addressed in a previous report \[[@B12]\].

There is some controversy regarding the impact of the donor\'s age on the outcome of renal transplantation from living donors. In our series, there was a negative impact on graft survival of kidneys obtained from donors above the age of 40 years. Similar observations were also reported by several investigators \[[@B9], [@B13], [@B14]\]. Reduced pre-donation GFR, higher blood pressure, and total cholesterol levels, usually associated with older age, were suggested as a possible explanation. However, patient and graft outcomes from older living kidney donors were reported as similar to those from younger donors despite lower GFR \[[@B15]\].

In an earlier report, it was observed that when the combined number of HLA-A, -B and -DR mismatches was considered, the influence of the degree of HLA incompatibility was significant \[[@B16]\]. In the current study, such an impact was not seen which is in agreement with a recently published report \[[@B9]\]. The increased number of patients who received a calcineurin inhibitor can provide an explanation. Nevertheless, the best outcomes, by far, were obtained from HLA identical siblings. Results of graft survival of kidneys obtained from 1-haplotype and 2-haplotype mismatched pairs were not different. This is in agreement with data from the collaborative transplant study (CTS) \[[@B17]\].

Evidence was provided that a tacrolimus-based triple therapy provided the best probability of graft survival at ten years. A similar finding was also reported by the CTS \[[@B16]\]. In their study, a combination of tacrolimus/azathioprine (Tac/Aza) provided a better result than that of tacrolimus/mycophenolate mofetil (Tac/MMF). A possible explanation is that while Tac/MMF can provide a more potent immunosuppression, Tac/Aza is associated with a reduced risk of infectious complications \[[@B18]\].

Our data demonstrate that the incidence and number of acute rejection episodes encountered during the first 3 months after transplantation had a significant negative impact on graft survival. This is also reflected in the inverse relationship between graft survival and the total dose of corticosteroids during the same time period. A long list of predisposing factors for acute rejection can be compiled. Nevertheless, there are no reliable method(s) to predict whether a given patient will have a rejection. On this basis, it was suggested that the routine utilization of an induction regimen could be of benefit. To this end, the use of an interleukin-2 receptor antibodies is attractive because of their potential role in the prevention of rejection with almost negligible side effects \[[@B19], [@B20]\]. In a prospective randomized controlled study with an extended follow-up, Sheashaa and associates reported that basiliximab induction reduces the incidence of acute rejection significantly. However, a noticeable effect on the long-term renal transplant outcome was not seen \[[@B21]\].

The independent and significant negative influence of the cumulative dose of corticosteroids received during the first 3 months after transplantation is not a surprise. Their multiple adverse effects on the patient\'s blood pressure, lipid profile, and glucose tolerance are well documented \[[@B22], [@B23]\]. Hence, studies were carried out to explore the feasibility of corticosteroid withdrawal or minimization. These had provided evidence of the clinical benefits from early or late steroid withdrawals without an untoward effect on graft survival \[[@B24]--[@B26]\]. In a meta-analysis by Knight and Morris, they reported that steroid avoidance after renal transplantation increases the risk of acute rejection but decreases the cardiovascular risks. They concluded that such protocols are justified with current immunosuppressive protocols in low-risk recipients \[[@B27]\]. A similar conclusion was reported by our group when a steroid-avoidance immunosuppression regimen was utilized for low-risk live-donor transplant recipients \[[@B3]\].

Despite the significant improvements in graft survival achieved by the introduction of calcineurin inhibitors, the nephrotoxicity of these agents had raised concern \[[@B28], [@B29]\]. In a longitudinal histological study, it was demonstrated that long-term calcineurin inhibitor nephrotoxicity is common and characterized by increasing small vessel-narrowing and progressive ischemic glomerulosclerosis \[[@B30]\]. This nephrotoxicity can account for the fact that reduction of early episodes of acute rejection did not result in a corresponding improvement in the long-term outcome. In our study, the excellent results obtained at 5 years after transplantation, followed by a steady decline in graft survival. This can be, at least partially, due to calcineurin inhibitor-induced nephrotoxicity. Several studies explored the possibility of calcineurin-inhibitor sparing and/or steroid avoidance immunosuppressive regimens. The best maintenance immunosuppressive regimen with calcineurin inhibitor and/or steroid sparing is a work in progress and awaits a longer follow-up. One strategy employs the utilization of a powerful agent for induction to be followed by withdrawal of the calcineurin inhibitor after a predetermined time. We have conducted a pilot study to determine the feasibility of steroid and calcineurin inhibitor-free regimen following live-donor kidney transplantation \[[@B31]\]. Alemtuzumab was used for induction. Tacrolimus was given for the first 2 months and replaced by sirolimus thereafter. Out of 41 recipients, 31 are enjoying steroid-free regimen of whom 21 patients are calcineurin inhibtor-free as well. This regimen proved to be effective with good patient acceptance and excellent patient and graft survival. The reported follow-up period of 28.3 ± 2.1 months is short. An extended observation period is necessary before making a final judgment.

In a previous report \[[@B32]\], the incidence of malignancy among our recipients was 3.9%. Kaposi sarcoma was the common type, and posttransplant lymphoproliferative disorder (PTLD) was the second most common one.

5. Conclusions {#sec5}
==============

Factors affecting graft survival following renal transplantation from living donors were studied by univariate as well as multivariate analysis. Five variables were identified as factors with an independent impact on graft survival. Excellent outcomes were obtained at 5 years following transplantation. Thereafter, a steady decline was observed presumably as a result of chronic allograft nephropathy. Since the current immunosuppressive regimens play a central role in its pathogenesis, relentless efforts should be made to define the optimal steroid and/or calcineurin inhibitors sparing protocols.

![Actuarial patient and graft survival. Patient survival was 89.7 ± 0.7% and 77.8 ± 1.2% years at 5 and 10 years, respectively. Graft survival was 86.7 ± 0.8% at 5 years and dropped to 65.5 ± 1.3% at 10 years.](BMRI2013-912413.001){#fig1}

![Log derivation of percentage of survival. The projected half-life for patients was 22 years and for grafts was 17.5 years.](BMRI2013-912413.002){#fig2}

![Graft survival relative to primary immunosuppressive regimen. Univariate analysis indicated that Tac-based triple therapy provided the best outcome.](BMRI2013-912413.003){#fig3}

###### 

\(a\) Graft survival relative to pretransplantation variables: personal factors. (b) Graft survival relative to pretransplantation variables: hematological factors. (c) Graft survival relative to pre-transplantation variables: immunologic factors. (d) Graft survival relative to pretransplantation variables: current and past medical disorders.

###### 

\(a\)  

  -----------------------------------------------------------------------------------------------------------------------------------
                             No. of\    5-year survival %   95% CI   10-year survival %   95% CI   *P*-value\           
                             patients                                                              (log rank)           
  -------------------------- ---------- ------------------- -------- -------------------- -------- ------------ ------- -------------
  Donor\'s sex                                                                                                           

   Male                      944        88.6                86.44    90.76                69.9     66.37        73.43   **0.012**

   Female                    1023       85.0                82.65    87.35                61.5     57.97        65.03   

  Donor\'s age (years)                                                                                                   

   ≤30                       772        87.7                85.35    90.05                68.5     64.58        72.42   **\<0.001**

   31--40                    627        87.9                85.16    90.64                69.6     65.29        73.91   

   41--50                    389        83.4                79.48    87.32                58.0     52.12        63.88   

   ≥50                       179        85.3                79.81    90.79                52.9     43.30        62.50   

  Recipient\'s sex                                                                                                       

   Male                      1466       87.6                85.84    89.46                64.7     54.9         74.50   **0.829**

   Female                    501        84.3                80.97    87.63                67.8     63.10        72.50   

  Recipient\'s age (years)                                                                                               

   ≤20                       378        84.4                80.68    88.12                59.0     52.92        65.08   **0.002**

   21--30                    709        88.6                86.25    90.95                66.9     62.78        71.02   

   31--40                    556        86.5                83.56    89.44                67.0     62.49        71.51   

   41--50                    270        85.7                81.39    90.01                67.4     60.54        74.26   

   ≥50                       54         86.7                75.53    97.87                71.2     52.78        89.62   

  The sex donor-recipient                                                                                                

   Male-male                 693        89.5                87.15    91.85                68.2     63.89        72.51   **0.082**

   Male-female               251        86.1                81.59    90.61                74.4     68.13        80.67   

   Female-male               773        85.9                83.35    88.45                61.5     57.38        65.62   

   Female-female             250        82.6                77.70    87.50                61.3     54.24        68.36   

  Donor relationship                                                                                                     

   Related                   1620       87.3                85.54    89.06                65.7     62.96        68.44   **0.651**

   Unrelated                 347        84.3                80.18    88.42                64.6     58.33        70.87   
  -----------------------------------------------------------------------------------------------------------------------------------

###### 

\(b\)

  ------------------------------------------------------------------------------------------------------------------------------------
                              No. of\    5-year survival %   95% CI   10-year survival %   95% CI   *P* value\           
                              patients                                                              (log rank)           
  --------------------------- ---------- ------------------- -------- -------------------- -------- ------------ ------- -------------
  ABO compatibility                                                                                                       

   Identical                  1579       87.3                85.54    89.06                65.8     63.06        68.54   **0.500**

   Different compatible       388        84.5                80.78    88.22                64.4     58.72        70.08   

  Type of blood transfusion                                                                                               

   No transfusion             1049       89.1                87.14    89.80                69.0     65.28        72.72   **\<0.001**

   Third party                906        84.2                81.65    83.03                62.8     59.47        66.13   

   Donor specific             12         ---                 ---      ---                  ---                           

  No. of blood transfusion                                                                                                

   No transfusion             1049       89.1                87.14    89.80                68.8     65.08        72.52   **0.001**

   1-2 times                  301        87.1                83.18    91.06                67.3     61.42        73.18   

   3-4                        265        82.1                77.40    86.80                64.4     58.13        70.67   

   ≥5                         352        83.3                79.18    87.42                57.8     52.31        63.29   
  ------------------------------------------------------------------------------------------------------------------------------------

###### 

\(c\)  

  ---------------------------------------------------------------------------------------------------------------------------------------------
                                     No. of\    5-year survival %   95% CI\   10-year survival %   95% CI\   *P* value\           
                                     patients                                                                (log rank)           
  ---------------------------------- ---------- ------------------- --------- -------------------- --------- ------------ ------- -------------
  HLA-A, B (class I)                                                                                                               

   0-MM                              153        93.2                89.08     97.32                71.4      62.38        80.42   **\<0.001**

   1-MM                              229        92.6                89.07     96.13                74.1      67.44        80.76   

   2-MM                              996        86.2                84.04     88.36                62.7      59.17        66.23   

   3-MM                              309        82.5                77.99     87.01                62.4      56.13        68.67   

   4-MM                              132        85.7                79.43     91.97                71.0      62.18        79.82   

  HLA-DR (class II)                                                                                                                

   0-MM                              201        91.5                87.58     95.42                77.6      69.56        85.64   **0.010**

   1-MM                              1720       86.7                84.94     88.46                64.5      61.76        67.24   

   2-MM                              2          ---                 ---       ---                  ---                            

  HLA (class I + II) MM                                                                                                            

   0-MM                              88         94.1                89.0      99.20                79.6      67.84        91.36   **0.001**

   1-MM                              102        93.8                89.09     98.50                68.0      57.02        78.98   

   2-MM                              234        90.0                86.08     93.92                71.3      64.64        77.96   

   3-MM                              968        86.2                83.85     88.55                62.8      59.08        66.52   

   4-MM                              290        82.4                77.89     86.91                62.0      55.53        68.47   

   5-MM                              131        85.6                79.33     91.87                69.3      60.28        78.32   

  HLA-A, B, DR (class I and II) MM                                                                                                 

   0/1/2                             424        91.8                89.06     94.54                72.1      67.00        77.20   **0.011**

   3/4/5/6                           1389       85.8                83.44     87.36                63.4      60.46        66.34   

  Genetic considerations                                                                                                           

   HLA-ID sibling                    152        94.4                92.64     96.16                79.2      70.18        88.22   **0.005**

   1-Haplotype MM (R)                1322       87.7                85.94     89.46                64.7      61.56        67.84   

   2-Haplotype MM (R + UR)           449        83.2                79.48     86.92                64.0      58.51        69.49   
  ---------------------------------------------------------------------------------------------------------------------------------------------

###### 

\(d\)  

  ------------------------------------------------------------------------------------------------------------------------------------------
                                     No. of\    5-year survival %   95% CI   10-year survival %   95% CI   *P* value\            
                                     patients                                                              (log rank)            
  ---------------------------------- ---------- ------------------- -------- -------------------- -------- ------------ -------- -----------
  Bilharziasis                                                                                                                    

   (i) Negative                      1442       87.6                85.84    89.36                65.9     62.76        69.04    **0.796**

   (ii) Positive                     525        84.6                81.46    87.74                64.4     59.89        68.91    

  Original kidney diseases                                                                                                        

   (i) Glomerulonephritis            214        82.8                73.74    88.09                63.5     56.05        70.95    **0.020**

   (ii) Chronic pyelonephritis       259        90.6                86.88    94.32                73.3     67.22        79.38    

   (iii) Nephrosclerosis             50         84.9                74.51    95.29                55.4     39.72        71.08    

   (iv) Obstructive uropathy         57         92.2                84.95    99.45                76.0     61.50        90.50    

   (v) Amyloidosis                   33         93.9                85.67    102.13               80.4     64.52        96.28    

   (vi) Congenital polycystic        51         93.4                86.15    100.65               55.8     37.57        74.03    

   (vii) Hypoplasia                  17         100.0               100.00   100.00               83.1     61.54        104.66   

   (viii) Others                     126        80.9                73.65    88.15                58.8     45.67        71.93    

   (ix) Not determined               1160       ---                 ---      ---                  ---      ---          ---      

  Types of glomerulonephritis (GN)                                                                                                

   (i) Mesangiocapillary GN          35         81.8                68.67    94.93                62.7     42.90        82.50    **0.701**

   (ii) Membranous GN                22         57.8                36.83    78.77                57.8     36.83        78.77    

   (iii) F.S.G.S.                    70         90.7                83.64    97.76                66.6     53.66        79.54    

   (iv) Mesangioproliferative GN     23         73.9                55.87    91.93                67.8     53.66        79.54    

   (v) Crescentic GN                 16         87.5                71.23    103.77               46.7     17.69        75.71    

   (vi) Hereditary nephritis         48         87.0                77.20    96.80                65.7     49.80        79.60    

  Pretransplant hypertension                                                                                                      

   (i) Normotensive                  826        87.2                84.85    89.55                64.6     60.48        68.72    **0.466**

   (ii) Hypertensive                 1141       86.4                84.24    88.56                66.1     62.77        69.43    

  No. of transplants received                                                                                                     

   (i) First                         1891       86.0                85.03    88.17                65.1     62.55        67.65    **0.242**

   (ii) Second                       73         90.0                82.94    97.06                77.8     67.22        88.38    

   (iii) Third                       3          ---                 ---      ---                  ---      ---                   
  ------------------------------------------------------------------------------------------------------------------------------------------

###### 

Graft survival relative to technical variables.

  -------------------------------------------------------------------------------------------------------------------------------------------
                                       No. of\    5-year survival %   95% CI   10-year survival %   95% CI   *P* value\           
                                       patients                                                              (log rank)           
  ------------------------------------ ---------- ------------------- -------- -------------------- -------- ------------ ------- -----------
  No. of renal arteries                                                                                                            

    (i) Single                         1749       86.8                85.23    88.37                66.0     63.26        68.74   **0.474**

   (ii) Multiple                       218        86.1                81.20    91.00                61.0     52.38        69.62   

  Total ischemia time (min)                                                                                                        

   \<30                                225        89.3                85.18    93.42                61.4     54.74        68.06   **0.039**

   30--60                              1506       86.2                84.44    87.96                65.7     62.76        68.64   

   \>60                                236        87.8                83.29    92.31                74.2     66.56        81.84   

  Time to diuresis                                                                                                                 

   (i) Immediate (\<10 min)            1806       87.2                85.63    88.77                66.0     63.45        68.55   **0.029**

   (ii) Delayed (\>10 min)             161        81.5                75.03    87.97                59.2     49.99        68.41   

  Primary urinary recontinuity                                                                                                     

   (i) Ureterovesical (Lead better)    170        77.1                70.44    83.76                57.8     49.76        65.84   **0.624**

   (ii) Ureterovesical (Leich Grieg)   1761       87.5                85.93    89.07                66.0     63.26        68.74   

   (iii) Ureteroureteral               29         92.0                81.42    102.58               74.7     57.06        92.34   

   (iv) Pyeloureteral                  3          ---                 ---      ---                  ---      ---                  

   (v) Ileal conduit                   4          ---                 ---      ---                  ---      ---                  
  -------------------------------------------------------------------------------------------------------------------------------------------

###### 

Graft survival relative to posttransplantation variables.

  -----------------------------------------------------------------------------------------------------------------------------------
                                            No. of\    5-year\      95% CI   10-year\     95% CI   *P* value\           
                                            patients   survival %            survival %            (log rank)           
  ----------------------------------------- ---------- ------------ -------- ------------ -------- ------------ ------- -------------
  Induction therapy                                                                                                      

   No                                       1108       86.5         84.34    88.66        64.6     61.66        67.54   **0.536**

   Yes                                      859        87.1         84.75    89.45        69.5     64.80        74.20   

  Primary immunosuppression                                                                                              

   (i) Aza-based (dual therapy)             309        82.2         77.69    86.71        58.3     52.42        64.18   **\<0.001**

   (ii) CsA-based (dual therapy)            303        84.8         79.12    90.48        57.8     49.76        65.84   

   (iii) CsA-based (triple therapy)         988        86.9         84.74    89.06        66.5     63.36        69.64   

   (iv) Tacrolimus-based (triple therapy)   217        91.6         88.27    94.93        86.2     80.91        91.49   

   (v) Sirolimus-based therapy              85         88.9         82.04    95.76        ---      ---                  

  Total steroid dose\                                                                                                    
  (during first 3 months)                                                                                               

   \<5 gm                                   1158       89.3         87.34    91.26        70.3     66.77        73.83   **\<0.001**

   5--10 gm                                 601        85.0         82.06    87.94        64.8     60.68        68.92   

   \>10 gm                                  208        77.9         72.02    83.78        46.9     39.65        54.15   

  No. of acute rejection episodes\                                                                                       
  (during first 3 months)                                                                                               

   (i) No                                   708        94.2         92.44    95.96        82.1     78.18        86.02   **\<0.001**

   (ii) One                                 661        89.6         87.25    91.95        69.4     65.28        73.52   

   (iii) ≥2                                 598        75.8         72.27    79.33        47.5     43.19        51.81   

  Urological complications                                                                                               

   (i) No                                   1816       87.0         85.43    88.57        65.9     63.35        68.45   **0.449**

   (ii) Yes                                 151        83.6         77.52    89.68        61.4     51.99        70.81   

  Post-transplant hypertension                                                                                           

   (i) Normotensive                         758        86.2         83.46    88.94        75.7     71.58        79.82   **\<0.001**

   (ii) Sustained hypertension              809        88.0         85.65    90.45        65.9     62.18        69.62   

   (iii) Newly developed hypertension       400        85.7         82.17    89.23        56.0     50.71        61.29   
  -----------------------------------------------------------------------------------------------------------------------------------

###### 

Cox proportional hazard analysis.

  -----------------------------------------------------------------------------------------------------------------------------
  Characteristic                                            Regression estimate\   S.E.    Relative risk\         *P* value
                                                            (*B*)                          Exp(*B*) (95% CI)      
  --------------------------------------------------------- ---------------------- ------- ---------------------- -------------
  Donor\'s age (years)                                                                                             

   \<30                                                     ---                    ---     1                       

   31--40                                                   −0.049                 0.097   0.952 (0.788, 1.150)   **0.609**

   41--50                                                   0.326                  0.109   1.385 (1.120, 1.714)   **0.003**

   \>50                                                     0.487                  0.145   1.628 (1.224, 2.164)   **\<0.001**

  Genetic considerations                                                                                           

   (i) HLA-ID siblings                                      ---                    ---     1                       

   (ii) 1-haplotype MM (R)                                  0.059                  0.203   1.099 (0.739, 1.635)   **0.641**

   (iii) 2-haplotype MM (R + UR)                            0.404                  0.211   1.498 (0.990, 2.267)   **0.056**

  No. of acute rejection episodes (during first 3 months)                                                          

   (i) No                                                   ---                    ---     1                       

   (ii) One                                                 0.779                  0.130   2.218 (1.689, 2.814)   **\<0.001**

   (iii) ≥2                                                 1.559                  0.131   4.754 (3.737, 6.141)   **\<0.001**

  Total steroid dose (during first 3 months)                                                                       

   \<5 gm                                                   ---                    ---     1                       

   5--10 gm                                                 −0.363                 0.100   0.696 (0.572, 0.846)   **0.001**

    \>10 gm                                                 −0.294                 0.135   0.745 (0.572, 0.972)   **0.030**

  Primary immunosuppression                                                                                        

   (i) Aza-based (dual therapy)                             ---                    ---     1                       

   (ii) CsA-based (dual therapy)                            −0.022                 0.139   0.978 (0.744, 1.285)   **0.872**

   (iii) CsA-based (triple therapy)                         −0.234                 0.114   0.791 (0.633, 0.989)   **0.039**

   (iv) Tacrolimus-based (triple therapy)                   −0.686                 0.228   0.504 (0.322, 0.787)   **0.003**
  -----------------------------------------------------------------------------------------------------------------------------

[^1]: Academic Editor: Gerald Brandacher
